Cryopreservative compositions and methods
US-2017172138-A1 · Jun 22, 2017 · US
US12543727B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12543727-B2 |
| Application number | US-202017594345-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 2, 2020 |
| Priority date | Apr 9, 2019 |
| Publication date | Feb 10, 2026 |
| Grant date | Feb 10, 2026 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A thawing solution has 0.1-50 g of a biomimetic material for controlling ice, 0-1.0 mol L −1 of a water-soluble sugar, and balance of a buffer solution. The biomimetic material for controlling ice is a material for controlling ice having an ice-philic group and a hydrophilic group. The hydrophilic group is a functional group that can form a non-covalent interaction with water molecules, and the ice-philic group is a functional group that can form a non-covalent interaction with ice. Using the thawing solution and the thawing reagent prepared from the biomimetic material for controlling ice, which material has ice-philic and hydrophilic properties, the growth and recrystallization of ice crystals can be effectively controlled, and damage to cells or tissue caused by uncontrolled growth of the ice crystals during recovery can be significantly ameliorated.
Opening claim text (preview).
The invention claimed is: 1 . A thawing solution comprising, per 100 mL: 0.1-50 g of a biomimetic ice growth inhibition material, a water-soluble saccharide at 0-1.0 mol L −1 and a balance of a buffer, wherein the biomimetic ice growth inhibition material is an atactic polyvinyl alcohol (PVA) having a syndiotacticity of 45%-65% and a molecular weight of 10 kDa-500 kDa, or a combination of said PVA with an amino acid, or with a polypeptide, or with a polyamino acid. 2 . The thawing solution according to claim 1 , wherein the amino acid is selected from one of or a combination of two or more of arginine, threonine, proline, lysine, histidine, glutamine, aspartic acid, and glycine; and/or the polyamino acid is a homopolymer of at least one selected from lysine, arginine, proline, threonine, histidine, glutamic acid, aspartic acid, and glycine; and/or the polypeptide is one or two or more of L-Thr-L-Arg (TR), L-Thr-L-Pro (TP), L-Arg-L-Thr (RT), L-Pro-L-Thr (PT), L-Thr-L-Arg-L-Thr (TRT), L-Thr-L-Pro-L-Thr (TPT), L-Ala-L-Ala-L-Thr (AAT) or L-Thr-L-Cys-L-Thr (TCT); and/or the PVA has a degree of hydrolysis of 80%-99%, 82%-87%, 87%-89%, 89%-99% or 98%-99%. 3 . The thawing solution according to claim 1 , wherein the content of the biomimetic ice growth inhibition material is 1.0-30 g; or the biomimetic ice growth inhibition material comprises 1.0-6.0 g of the PVA; or the biomimetic ice growth inhibition material comprises 1.0-30 g of the amino acid; or the biomimetic ice growth inhibition material comprises 0.1-9.0 g of the polyamino acid; or the biomimetic ice growth inhibition material comprises 1.0-13 g of the polypeptide; or the biomimetic ice growth inhibition material is a combination of the PVA with the amino acid, the polypeptide and/or the polyamino acid. 4 . The thawing solution according to claim 3 , wherein the amino acid is a combination of arginine and threonine. 5 . The thawing solution according to claim 4 , wherein the water-soluble saccharide is selected from sucrose, trehalose, a water-soluble cellulose and a polysucrose. 6 . The thawing solution according to claim 1 , wherein the water-soluble saccharide is at least one of a non-reducing disaccharide, a water-soluble polysaccharide and a glycoside; and/or the buffer is selected from at least one of DPBS, hepes-buffered HTF buffer and other cell buffers. 7 . The thawing solution according to claim 1 comprising, wherein the PVA has a syndiotacticity of 50%-55% and a molecular weight of 13 kDa-23 kDa.
Related publications grouped by family.
Answers are generated from the same data shown on this page.